Compare AAP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | IDYA |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2002 | 2019 |
| Metric | AAP | IDYA |
|---|---|---|
| Price | $51.34 | $32.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | ★ $53.50 | $51.21 |
| AVG Volume (30 Days) | ★ 1.4M | 767.9K |
| Earning Date | 05-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ 113.01 | 61.90 |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $8,601,000,000.00 | $218,710,000.00 |
| Revenue This Year | $0.43 | N/A |
| Revenue Next Year | $2.52 | $191.08 |
| P/E Ratio | $74.40 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $28.89 | $13.45 |
| 52 Week High | $70.00 | $39.28 |
| Indicator | AAP | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 48.96 |
| Support Level | $49.18 | $29.29 |
| Resistance Level | $52.10 | $34.86 |
| Average True Range (ATR) | 2.13 | 1.56 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 61.64 | 48.90 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.